Based on the exciting early experiences with CAR T cell therapy, CTL019, a CD19 CAR T cell construct owned by Novartis, received FDA breakthrough therapy designation in July 2014 for the treatment of relapsed/refractory ALL. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.